ECRI engineering manager receives excellence award

The ECRI Institute's Health Devices Group engineering manager, Erin M. Sparnon, MEng, will be honored with the 2014 ACCE-HIMSS Excellence in Clinical Engineering and Information Technology Synergies Award. The award recognizes leadership in implementing and promoting alliances between the clinical engineering and information technology professions.

Sparnon was chosen because of her work as an advocate for patient safety in health IT and medical device integration, according to a release. This includes her efforts to evaluate and analyze safety reports on IT-based medical technologies, her participation in clinical engineering and IT communities and her integral role on several standards-based committees for health IT and medical device integration.

Sparnon also helped establish health IT research priorities and protocols for ECRI Institute's collaborative program, the Partnership for Health IT Patient Safety, a private sector initiative with the overarching goal of advancing the safety and safe use of health IT to improve patient care.

Sparnon will receive the reward at the HIMSS annual conference in April in Chicago.

Beth Walsh,

Editor

Editor Beth earned a bachelor’s degree in journalism and master’s in health communication. She has worked in hospital, academic and publishing settings over the past 20 years. Beth joined TriMed in 2005, as editor of CMIO and Clinical Innovation + Technology. When not covering all things related to health IT, she spends time with her husband and three children.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.